Salivary E-cadherin, Calprotectin, and Matrix Metalloproteinase-9 Levels in Recurrent Aphthous Stomatitis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSelin Yeşiltepe

About this trial

The goal of this observational cross-sectional study is to determine the salivary levels of E-cadherin, Calprotectin, and Matrix Metalloproteinase-9 (MMP-9) in patients with Recurrent Aphthous Stomatitis (RAS) and to compare them with those of healthy controls.

The main questions it aims to answer are:

Are the salivary levels of E-cadherin, Calprotectin, and MMP-9 significantly different in patients with minor RAS compared to healthy controls?

Can these salivary proteins serve as biomarkers involved in the pathogenesis of minor RAS?

Researchers will compare patients with minor RAS and healthy individuals to determine whether differences in salivary E-cadherin, Calprotectin, and MMP-9 levels are associated with the presence of disease.

Participants will:

Provide unstimulated saliva samples using a saliva swab

Undergo clinical evaluation for periodontal status (Community Periodontal Index - CPI) and caries experience (DMFT index)

Collected saliva samples will be stored at -80°C until analysis. The concentrations of the investigated proteins will be measured using ELISA kits, and total protein levels will be determined using a colorimetric protein assay.

The relationships among the salivary concentrations of the investigated proteins, as well as their associations with demographic variables such as age and sex, will be analyzed.

Eligibility criteria

Qualifiers

Participants aged 18 years or older

Clinically diagnosed with minor recurrent aphthous stomatitis (RAS) (defined as having a history of at least three RAS episodes within the past year)

Systemically healthy (i.e., without any diagnosed systemic disease)

No history of tobacco use

Disqualifiers

Use of any pharmacological treatment within the past 3 months

Use of antiseptic mouthwash within the past 3 months

Pregnant or lactating individuals, or those currently using oral contraceptives

History of systemic diseases associated with oral ulcerations such as Crohn's disease, ulcerative colitis, celiac disease, or Behçet's disease

Trial design

Treatments tested in this trial

  • ELISA

Treatment groups

102 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Selin Yeşiltepe

Lead sponsor

Aydin Adnan Menderes University

Sponsor institution

Aydın Adnan Menderes University Scientific Research Projects Unit

Collaborator

Aydin Adnan Menderes University

Collaborator